S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Trump’s “Tax Free” Retirement Strategy (Ad)
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
He Is Giving Away Bitcoin (Ad)
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Trump’s “Tax Free” Retirement Strategy (Ad)
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
He Is Giving Away Bitcoin (Ad)
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Trump’s “Tax Free” Retirement Strategy (Ad)
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
He Is Giving Away Bitcoin (Ad)
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Trump’s “Tax Free” Retirement Strategy (Ad)
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
He Is Giving Away Bitcoin (Ad)
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Free Trial

Monte Rosa Therapeutics (GLUE) Competitors

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)
Free GLUE Stock Alerts
$6.57
-0.64 (-8.88%)
(As of 04/15/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

GLUE vs. MGX, AURA, CRBU, ALVO, MGTX, ADPT, HUMA, AVXL, IVVD, and LXEO

Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Metagenomi (MGX), Aura Biosciences (AURA), Caribou Biosciences (CRBU), Alvotech (ALVO), MeiraGTx (MGTX), Adaptive Biotechnologies (ADPT), Humacyte (HUMA), Anavex Life Sciences (AVXL), Invivyd (IVVD), and Lexeo Therapeutics (LXEO). These companies are all part of the "biological products, except diagnostic" industry.

Monte Rosa Therapeutics vs.

Monte Rosa Therapeutics (NASDAQ:GLUE) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Monte Rosa Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 67.43%. Metagenomi has a consensus target price of $21.40, indicating a potential upside of 150.59%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than Monte Rosa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Metagenomi
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Monte Rosa Therapeutics received 2 more outperform votes than Metagenomi when rated by MarketBeat users. However, 100.00% of users gave Metagenomi an outperform vote while only 37.50% of users gave Monte Rosa Therapeutics an outperform vote.

CompanyUnderperformOutperform
Monte Rosa TherapeuticsOutperform Votes
9
37.50%
Underperform Votes
15
62.50%
MetagenomiOutperform Votes
7
100.00%
Underperform Votes
No Votes

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 1 mentions for Metagenomi. Monte Rosa Therapeutics' average media sentiment score of 1.30 beat Metagenomi's score of 0.94 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Monte Rosa Therapeutics Positive
Metagenomi Positive

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 5.3% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Metagenomi's return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa TherapeuticsN/A -65.93% -47.35%
Metagenomi N/A N/A N/A

Metagenomi has higher revenue and earnings than Monte Rosa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa TherapeuticsN/AN/A-$135.35M-$2.64-2.49
Metagenomi$44.76M7.15-$68.25MN/AN/A

Summary

Metagenomi beats Monte Rosa Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLUE vs. The Competition

Export to Excel
MetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$329.49M$2.63B$4.83B$7.49B
Dividend YieldN/A2.27%5.53%3.96%
P/E Ratio-2.4944.14248.9219.11
Price / SalesN/A329.142,495.3991.23
Price / CashN/A139.5633.2728.20
Price / Book1.843.924.674.26
Net Income-$135.35M-$39.38M$100.02M$210.92M
7 Day Performance-16.41%-5.64%-4.44%-4.38%
1 Month Performance2.50%-4.93%-2.92%-2.08%
1 Year Performance-4.09%11.36%12.64%6.73%

Monte Rosa Therapeutics Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGX
Metagenomi
3.0581 of 5 stars		$10.42
+5.9%		$21.40
+105.4%		N/A$390.44M$44.76M0.00236Gap Down
AURA
Aura Biosciences
1.3101 of 5 stars		$7.84
+8.0%		$21.00
+167.9%		-13.2%$388.08MN/A-4.0870Short Interest ↑
CRBU
Caribou Biosciences
1.8391 of 5 stars		$4.46
+2.3%		$22.50
+404.5%		-11.1%$402.83M$34.48M-3.08158News Coverage
Positive News
ALVO
Alvotech
0 of 5 stars		$11.93
-0.7%		$12.67
+6.2%		+17.3%$372.81M$91.43M-4.911,026
MGTX
MeiraGTx
4.366 of 5 stars		$5.72
+2.7%		$25.67
+348.7%		+3.0%$367.34M$14.02M-3.89419Positive News
ADPT
Adaptive Biotechnologies
3.8079 of 5 stars		$2.93
+3.5%		$6.80
+132.1%		-63.2%$425.11M$170.28M-1.88709Short Interest ↑
HUMA
Humacyte
1.6765 of 5 stars		$3.04
-1.9%		$8.00
+163.2%		-11.7%$362.00M$1.57M-2.84164Short Interest ↑
Gap Up
AVXL
Anavex Life Sciences
3.3633 of 5 stars		$4.39
flat		$40.00
+811.2%		-46.3%$360.46MN/A-8.1340Short Interest ↑
IVVD
Invivyd
2.7644 of 5 stars		$3.02
-1.3%		$11.33
+275.3%		+140.2%$360.05MN/A-1.6784Short Interest ↑
High Trading Volume
LXEO
Lexeo Therapeutics
1.6951 of 5 stars		$13.45
+2.2%		$20.80
+54.6%		N/A$358.71M$650,000.000.0058Short Interest ↑

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:GLUE) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Investment of the Decade…
Porter & Company
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Paradigm Press
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
[BUY ALERT] Our #1 A.I. Stock for April
Behind the Markets